The Medicines Stock Price, News & Analysis (NASDAQ:MDCO)

$26.00 -0.21 (-0.80 %)
(As of 12/12/2017 03:07 AM ET)
Previous Close$26.21
Today's Range$25.93 - $26.70
52-Week Range$25.40 - $55.95
Volume1.58 million shs
Average Volume1.43 million shs
Market Capitalization$1.91 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.7

About The Medicines (NASDAQ:MDCO)

The Medicines logoThe Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin). It also has a pipeline of products in development, including Carbavance, inclisiran and MDCO-700. Carbavance is used for the treatment of hospitalized patients with gram-negative bacterial infections. Inclisiran is used for the treatment of hypercholesterolemia. MDCO-700 includes sedative-hypnotic, which is used to induce and maintain sedation for procedural care and general anesthesia for surgical care. In addition to these products and products in development, it has a portfolio of generic drugs.

Receive MDCO News and Ratings via Email

Sign-up to receive the latest news and ratings for MDCO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Generic Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:MDCO
CUSIP58468810
Phone973-290-6000

Debt

Debt-to-Equity Ratio3.42%
Current Ratio2.31%
Quick Ratio1.79%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$167.84 million
Price / Sales11.29
Cash FlowN/A
Price / CashN/A
Book Value$9.21 per share
Price / Book2.82

Profitability

Trailing EPS($9.13)
Net Income$-119,110,000.00
Net Margins-767.94%
Return on Equity-174.68%
Return on Assets-48.00%

Miscellaneous

Employees410
Outstanding Shares72,900,000

The Medicines (NASDAQ:MDCO) Frequently Asked Questions

What is The Medicines' stock symbol?

The Medicines trades on the NASDAQ under the ticker symbol "MDCO."

How were The Medicines' earnings last quarter?

The Medicines Company (NASDAQ:MDCO) issued its quarterly earnings results on Wednesday, October, 25th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.37) by $0.95. The firm had revenue of $16.87 million for the quarter, compared to analyst estimates of $26.06 million. The Medicines had a negative return on equity of 174.68% and a negative net margin of 767.94%. The firm's quarterly revenue was down 55.1% on a year-over-year basis. During the same period last year, the company earned ($0.64) EPS. View The Medicines' Earnings History.

When will The Medicines make its next earnings announcement?

The Medicines is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for The Medicines.

Where is The Medicines' stock going? Where will The Medicines' stock price be in 2017?

9 brokerages have issued 12 month price objectives for The Medicines' shares. Their predictions range from $44.00 to $85.00. On average, they expect The Medicines' share price to reach $55.25 in the next year. View Analyst Ratings for The Medicines.

What are Wall Street analysts saying about The Medicines stock?

Here are some recent quotes from research analysts about The Medicines stock:

  • 1. According to Zacks Investment Research, "The Medicines Co. recently received FDA approval of Vabomere which is a huge positive for the company given the lucrative market it targets. The company also has a blockbuster candidate, Inclisiran, in its portfolio. However, we await a clearer picture of the commercial potential of Vabomere and  Inclisiran, if approved. The company’s shares have underperformed the industry so far this year. The company is facing generic competition for its flagship product, Angiomax. With Angiomax sales eroding due to presence of generics, the company’s ability to successfully develop and bring new products to the market is important for growth. Any regulatory setbacks would weigh heavily on the stock. Meanwhile, loss estimates have widened ahead of the company's Q3 earnings results. The company has a negative record of earnings surprises in recent quarters." (10/10/2017)
  • 2. Jefferies Group LLC analysts commented, " ACC (Mar 17-19) will be a key meeting for inclisiran, where MDCO will detail full 6-mo data for ORION-1 and AMGN will present the FOURIER data. Data from the latter should help guide PIII development for inclisiran, for which MDCO continues to seek a partner. On positive FOURIER results, we lower our risk-discount on inclisiran and our PT increases to $62 (v. $49 prev)." (3/1/2017)

Who are some of The Medicines' key competitors?

Who are The Medicines' key executives?

The Medicines' management team includes the folowing people:

  • Fredric N. Eshelman Ph.D., Executive Chairman of the Board (Age 68)
  • Stuart A. Kingsley, President, Chief Operating Officer (Age 53)
  • Clive A. Meanwell M.D. Ph.D., Chief Executive Officer, Director (Age 59)
  • William Bernard O'Connor, Chief Financial Officer (Age 58)
  • Christopher T. Cox, Executive Vice President, Chief Corporate Development Officer (Age 52)
  • Jeffrey Frazier, Executive Vice President, Chief Human Strategy Officer (Age 54)
  • Stephen M. Rodin J.D., General Counsel, Secretary (Age 41)
  • Paris Panayiotopoulos, Director (Age 43)
  • William W. Crouse, Independent Director (Age 74)
  • Alexander J. Denner Ph.D., Independent Director (Age 47)

Who owns The Medicines stock?

The Medicines' stock is owned by a number of of institutional and retail investors. Top institutional investors include Westfield Capital Management Co. LP (3.40%), Iridian Asset Management LLC CT (2.43%), Pinnacle Associates Ltd. (1.73%), Macquarie Group Ltd. (1.35%), Eagle Asset Management Inc. (1.12%) and Elk Creek Partners LLC (0.95%). Company insiders that own The Medicines stock include Alexander J Denner, Armin M Kessler, Christopher T Cox, Clive Meanwell, Elizabeth H S Wyatt, Fredric N Eshelman, Hiroaki Shigeta, Melvin K Spigelman, William Bernard O'connor and William Crouse. View Institutional Ownership Trends for The Medicines.

Who sold The Medicines stock? Who is selling The Medicines stock?

The Medicines' stock was sold by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, Iridian Asset Management LLC CT, Antipodean Advisors LLC, First Eagle Investment Management LLC, New York State Common Retirement Fund, Principal Financial Group Inc., Iguana Healthcare Management LLC and Great West Life Assurance Co. Can. View Insider Buying and Selling for The Medicines.

Who bought The Medicines stock? Who is buying The Medicines stock?

The Medicines' stock was bought by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, Pictet Asset Management Ltd., Macquarie Group Ltd., University of Notre Dame DU Lac, Granahan Investment Management Inc. MA, Elk Creek Partners LLC, Fox Run Management L.L.C. and Crossmark Global Holdings Inc.. Company insiders that have bought The Medicines stock in the last two years include Alexander J Denner, Christopher T Cox and Fredric N Eshelman. View Insider Buying and Selling for The Medicines.

How do I buy The Medicines stock?

Shares of The Medicines can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is The Medicines' stock price today?

One share of The Medicines stock can currently be purchased for approximately $26.00.

How big of a company is The Medicines?

The Medicines has a market capitalization of $1.91 billion and generates $167.84 million in revenue each year. The company earns $-119,110,000.00 in net income (profit) each year or ($9.13) on an earnings per share basis. The Medicines employs 410 workers across the globe.

How can I contact The Medicines?

The Medicines' mailing address is 8 SYLVAN WAY, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-290-6000 or via email at [email protected]


MarketBeat Community Rating for The Medicines (MDCO)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  348 (Vote Outperform)
Underperform Votes:  201 (Vote Underperform)
Total Votes:  549
MarketBeat's community ratings are surveys of what our community members think about The Medicines and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

The Medicines (NASDAQ:MDCO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.822.822.82
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $54.40$54.40$55.40$55.50
Price Target Upside: 80.31% upside67.95% upside46.87% upside35.17% upside

The Medicines (NASDAQ:MDCO) Consensus Price Target History

Price Target History for The Medicines (NASDAQ:MDCO)

The Medicines (NASDAQ:MDCO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/29/2017OppenheimerUpgradeMarket Perform -> Buy$50.00HighView Rating Details
11/30/2017CitigroupUpgradeSell -> OutperformHighView Rating Details
10/26/2017Jefferies GroupReiterated RatingBuy$54.00N/AView Rating Details
10/23/2017GuggenheimInitiated CoverageBuy$45.00N/AView Rating Details
9/20/2017Chardan CapitalReiterated RatingBuy$85.00LowView Rating Details
8/10/2017CowenReiterated RatingBuy$61.00 -> $54.00HighView Rating Details
5/23/2017CIBCSet Price Target$50.00MediumView Rating Details
3/20/2017HC WainwrightReiterated RatingBuy$60.00HighView Rating Details
3/18/2017J P Morgan Chase & CoReiterated RatingBuyHighView Rating Details
3/1/2017Royal Bank of CanadaReiterated RatingBuyN/AView Rating Details
11/8/2016Leerink SwannReiterated RatingOutperform$53.00 -> $50.00N/AView Rating Details
7/12/2016Bank of AmericaReiterated RatingBuyN/AView Rating Details
(Data available from 12/12/2015 forward)

Earnings

The Medicines (NASDAQ:MDCO) Earnings History and Estimates Chart

Earnings by Quarter for The Medicines (NASDAQ:MDCO)

The Medicines (NASDAQ MDCO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018($1.32)N/AView Earnings Details
10/25/2017Q3 2017($1.37)($0.42)$26.06 million$16.87 millionViewN/AView Earnings Details
8/9/2017Q2 2017($1.29)($5.52)$29.64 million$18.74 millionViewListenView Earnings Details
4/26/2017Q1 2017($1.13)($1.44)$37.76 million$24.20 millionViewN/AView Earnings Details
2/28/2017Q416($1.43)($1.29)$26.91 million$25.20 millionViewListenView Earnings Details
10/26/2016Q316($1.38)($0.64)$37.26 million$37.60 millionViewListenView Earnings Details
7/27/2016Q216($1.16)($0.62)$41.93 million$54.70 millionViewListenView Earnings Details
5/9/2016Q116($0.89)($1.03)$48.96 million$50.30 millionViewListenView Earnings Details
2/17/2016Q415($1.54)($0.88)$64.11 million$67.20 millionViewN/AView Earnings Details
11/3/2015Q315($0.88)($0.90)$68.58 million$72.70 millionViewListenView Earnings Details
7/29/2015Q215($0.20)($0.74)$122.58 million$90.50 millionViewListenView Earnings Details
5/5/2015Q115($0.68)($0.02)$138.78 million$126.50 millionViewListenView Earnings Details
2/18/2015Q414($0.84)$0.11$188.55 million$191.00 millionViewListenView Earnings Details
10/22/2014Q314($0.10)$0.10$188.30 million$172.40 millionViewListenView Earnings Details
7/23/2014Q214($0.07)$0.22$183.75 million$183.80 millionViewListenView Earnings Details
4/23/2014Q114($0.13)$0.22$175.60 million$177.20 millionViewListenView Earnings Details
2/19/2014Q413$0.11$0.26$182.60 million$185.00 millionViewListenView Earnings Details
10/23/2013Q313$0.24$0.47$173.86 million$173.45 millionViewListenView Earnings Details
7/24/2013Q2 2013$0.33$0.50$168.70 million$172.00 millionViewListenView Earnings Details
4/24/2013Q1 2013($0.26)$0.31$152.63 million$155.80 millionViewListenView Earnings Details
2/20/2013Q4 2012$0.28$0.38$146.09 million$159.50 millionViewListenView Earnings Details
10/24/2012$0.39$0.40ViewN/AView Earnings Details
7/25/2012$0.22$0.46ViewN/AView Earnings Details
4/25/2012$0.14$0.27ViewN/AView Earnings Details
2/22/2012$0.24$0.52ViewN/AView Earnings Details
10/26/2011$0.20$0.17ViewN/AView Earnings Details
7/27/2011$0.31$0.21ViewN/AView Earnings Details
4/27/2011$0.40$0.45ViewN/AView Earnings Details
2/16/2011$0.24$0.30ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

The Medicines (NASDAQ:MDCO) Earnings Estimates

2017 EPS Consensus Estimate: ($5.62)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($1.36)($1.06)($1.21)
Q2 20173($1.40)($1.10)($1.23)
Q3 20173($1.79)($1.55)($1.65)
Q4 20173($1.72)($1.26)($1.53)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for The Medicines (NASDAQ:MDCO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

The Medicines (NASDAQ MDCO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.22%
Insider Trades by Quarter for The Medicines (NASDAQ:MDCO)
Institutional Ownership by Quarter for The Medicines (NASDAQ:MDCO)

The Medicines (NASDAQ MDCO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/8/2017Fredric N EshelmanInsiderBuy200,000$26.56$5,312,000.00View SEC Filing  
11/29/2017Alexander J DennerDirectorBuy170,000$30.03$5,105,100.00View SEC Filing  
2/7/2017William Bernard O'connorCFOSell25,833$46.20$1,193,484.60View SEC Filing  
12/8/2016Christopher T CoxEVPBuy105,500$33.20$3,502,600.00View SEC Filing  
12/8/2016Fredric N EshelmanDirectorBuy621,720$33.77$20,995,484.40View SEC Filing  
9/21/2016Clive MeanwellCEOSell8,623$40.00$344,920.00View SEC Filing  
9/1/2016Clive MeanwellCEOSell1,377$40.00$55,080.00View SEC Filing  
8/24/2016Clive MeanwellCEOSell20,000$40.00$800,000.00View SEC Filing  
7/11/2016Hiroaki ShigetaDirectorSell3,849$38.50$148,186.50View SEC Filing  
6/10/2016Christopher T CoxEVPBuy45,985$37.90$1,742,831.50View SEC Filing  
6/7/2016Christopher T CoxEVPBuy53,340$37.55$2,002,917.00View SEC Filing  
5/24/2016Melvin K SpigelmanDirectorSell15,000$37.00$555,000.00View SEC Filing  
5/16/2016Clive MeanwellCEOSell10,000$35.00$350,000.00View SEC Filing  
5/16/2016William CrouseDirectorSell15,000$35.15$527,250.00View SEC Filing  
5/13/2016Elizabeth H S WyattDirectorSell15,000$34.07$511,050.00View SEC Filing  
5/12/2016Fredric N EshelmanDirectorBuy300,000$33.68$10,104,000.00View SEC Filing  
3/7/2016Armin M KesslerDirectorSell8,100$34.82$282,042.00View SEC Filing  
11/13/2015Robert G. SavageDirectorSell5,000$39.34$196,700.00View SEC Filing  
9/3/2015Glenn SblendorioCFOSell25,000$42.00$1,050,000.00View SEC Filing  
8/31/2015Clive MeanwellCEOSell49,998$39.36$1,967,921.28View SEC Filing  
8/31/2015Glenn SblendorioCFOSell114,495$39.75$4,551,176.25View SEC Filing  
8/31/2015Melvin K. SpigelmanDirectorSell20,000$40.50$810,000.00View SEC Filing  
8/31/2015William Bernard O'connorSVPSell35,451$40.00$1,418,040.00View SEC Filing  
7/1/2015Clive MeanwellCEOSell16,667$28.39$473,176.13View SEC Filing  
6/25/2015Glenn SblendorioCFOSell3,305$32.00$105,760.00View SEC Filing  
6/8/2015Hiroaki ShigetaDirectorSell7,500$28.99$217,425.00View SEC Filing  
5/20/2015Robert G SavageDirectorSell15,000$26.78$401,700.00View SEC Filing  
4/16/2015William Bernard O'connorSVPSell1,281$30.00$38,430.00View SEC Filing  
4/1/2015Clive MeanwellCEOSell16,667$27.58$459,675.86View SEC Filing  
3/30/2015Elizabeth H S WyattDirectorSell20,000$28.08$561,600.00View SEC Filing  
3/23/2015Clive MeanwellCEOSell16,667$30.62$510,343.54View SEC Filing  
3/23/2015Glenn SblendorioCFOSell34,773$30.78$1,070,312.94View SEC Filing  
3/2/2015William Bernard O'connorSVPSell2,988$28.78$85,994.64View SEC Filing  
3/3/2014William Bernard O'connorSVPSell2,968$30.31$89,960.08View SEC Filing  
1/21/2014Paul Michael AntinoriVPSell37,883$38.02$1,440,311.66View SEC Filing  
1/15/2014William Bernard O'connorSVPSell4,427$39.15$173,317.05View SEC Filing  
1/10/2014William Bernard O'connorSVPSell72,384$40.00$2,895,360.00View SEC Filing  
1/7/2014Clive MeanwellCEOSell27,929$38.13$1,064,932.77View SEC Filing  
1/3/2014Clive MeanwellCEOSell57,516$38.16$2,194,810.56View SEC Filing  
12/9/2013William CrouseDirectorSell12,500$38.00$475,000.00View SEC Filing  
12/5/2013Glenn SblendorioCFOSell8,516$38.50$327,866.00View SEC Filing  
12/2/2013Clive MeanwellCEOSell10,000$36.58$365,800.00View SEC Filing  
11/26/2013Clive MeanwellCEOSell135,000$36.70$4,954,500.00View SEC Filing  
10/23/2013William Bernard O'connorSVPSell6,354$35.00$222,390.00View SEC Filing  
9/13/2013Paul Michael AntinoriVPSell73,500$34.50$2,535,750.00View SEC Filing  
9/3/2013Clive MeanwellCEOSell7,500$31.85$238,875.00View SEC Filing  
8/1/2013Clive MeanwellCEOSell7,500$31.26$234,450.00View SEC Filing  
7/8/2013Paul Michael AntinoriVPSell36,000$33.00$1,188,000.00View SEC Filing  
7/1/2013Clive MeanwellCEOSell7,500$31.25$234,375.00View SEC Filing  
6/11/2013Paul Michael AntinoriVPSell109,973$33.29$3,661,001.17View SEC Filing  
5/29/2013Armin M KesslerDirectorSell8,750$33.05$289,187.50View SEC Filing  
5/10/2013Glenn SblendorioCFOSell2,709$37.00$100,233.00View SEC Filing  
5/9/2013Paul Michael AntinoriVPSell35,000$34.90$1,221,500.00View SEC Filing  
5/9/2013William Bernard O'connorSVPSell29,654$35.00$1,037,890.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

The Medicines (NASDAQ MDCO) News Headlines

Source:
DateHeadline
The Medicines Company (MDCO) Insider Fredric N. Eshelman Buys 200,000 SharesThe Medicines Company (MDCO) Insider Fredric N. Eshelman Buys 200,000 Shares
www.americanbankingnews.com - December 11 at 8:26 PM
Immunocores IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal MelanomaImmunocore's IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma
feeds.benzinga.com - December 11 at 8:03 AM
Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical ActivityBlueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity
www.prnewswire.com - December 10 at 8:18 AM
The Medicines Company (MDCO) Receives Average Recommendation of "Buy" from AnalystsThe Medicines Company (MDCO) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 8 at 3:52 PM
$20.38 Million in Sales Expected for The Medicines Company (MDCO) This Quarter$20.38 Million in Sales Expected for The Medicines Company (MDCO) This Quarter
www.americanbankingnews.com - December 5 at 8:37 AM
FY2017 EPS Estimates for The Medicines Company Decreased by Analyst (MDCO)FY2017 EPS Estimates for The Medicines Company Decreased by Analyst (MDCO)
www.americanbankingnews.com - December 4 at 1:52 AM
The Medicines Company (MDCO) Expected to Post Earnings of -$1.48 Per ShareThe Medicines Company (MDCO) Expected to Post Earnings of -$1.48 Per Share
www.americanbankingnews.com - December 3 at 11:14 AM
The Medicines (MDCO) Rating Increased to Hold at ValuEngineThe Medicines (MDCO) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - December 3 at 8:14 AM
The Medicines Company to Post FY2021 Earnings of $0.83 Per Share, Oppenheimer Forecasts (MDCO)The Medicines Company to Post FY2021 Earnings of $0.83 Per Share, Oppenheimer Forecasts (MDCO)
www.americanbankingnews.com - December 2 at 10:00 AM
Melinta to buy The Medicines Cos infectious disease business for $265M - Seeking AlphaMelinta to buy The Medicines Co's infectious disease business for $265M - Seeking Alpha
seekingalpha.com - December 1 at 4:41 PM
Oppenheimer Raises Its Prognosis For The Medicines Company - BenzingaOppenheimer Raises Its Prognosis For The Medicines Company - Benzinga
www.benzinga.com - December 1 at 4:41 PM
The Medicines (MDCO) Raised to Outperform at CitigroupThe Medicines (MDCO) Raised to Outperform at Citigroup
www.americanbankingnews.com - November 30 at 6:10 PM
Medicines Company to Sell Infectious Disease Unit to MelintaMedicines Company to Sell Infectious Disease Unit to Melinta
www.zacks.com - November 30 at 5:30 PM
Oppenheimer Raises Its Prognosis For The Medicines CompanyOppenheimer Raises Its Prognosis For The Medicines Company
feeds.benzinga.com - November 30 at 1:44 PM
The Medicines (MDCO) Upgraded at OppenheimerThe Medicines (MDCO) Upgraded at Oppenheimer
www.americanbankingnews.com - November 30 at 12:00 PM
Insider Buying: The Medicines Company (MDCO) Director Buys 170,000 Shares of StockInsider Buying: The Medicines Company (MDCO) Director Buys 170,000 Shares of Stock
www.americanbankingnews.com - November 30 at 10:30 AM
The Medicines Company (MDCO): Time For A Financial Health CheckThe Medicines Company (MDCO): Time For A Financial Health Check
finance.yahoo.com - November 29 at 5:49 PM
Here's How Alnylam Pharmaceuticals, Inc. Crushed It in 2017Here's How Alnylam Pharmaceuticals, Inc. Crushed It in 2017
finance.yahoo.com - November 29 at 5:49 PM
Why Medicines Co. Is Tumbling Despite $270 Million DealWhy Medicines Co. Is Tumbling Despite $270 Million Deal
finance.yahoo.com - November 29 at 5:49 PM
ETFs with exposure to The Medicines Co. : November 24, 2017ETFs with exposure to The Medicines Co. : November 24, 2017
finance.yahoo.com - November 24 at 5:18 PM
NeuroVive Pharmaceutical AB Interim Report January - September 2017NeuroVive Pharmaceutical AB Interim Report January - September 2017
www.prnewswire.com - November 21 at 2:51 AM
The Medicines Target of Unusually High Options Trading (MDCO)The Medicines Target of Unusually High Options Trading (MDCO)
www.americanbankingnews.com - November 20 at 3:56 AM
The Medicines Company Names Dr. Fred Eshelman as Executive Chairman; Appoints Geno Germano to Its Board of ... - Business Wire (press release)The Medicines Company Names Dr. Fred Eshelman as Executive Chairman; Appoints Geno Germano to Its Board of ... - Business Wire (press release)
www.businesswire.com - November 17 at 8:33 PM
Zacks: Analysts Expect The Medicines Company (MDCO) to Post -$1.51 EPSZacks: Analysts Expect The Medicines Company (MDCO) to Post -$1.51 EPS
www.americanbankingnews.com - November 15 at 3:24 AM
BRIEF-SymBio Pharmaceuticals says arbitration against The Medicines CompanyBRIEF-SymBio Pharmaceuticals says arbitration against The Medicines Company
www.reuters.com - November 13 at 8:50 PM
BRIEF-SymBio Pharmaceuticals says arbitration against The Medicines Company - ReutersBRIEF-SymBio Pharmaceuticals says arbitration against The Medicines Company - Reuters
www.reuters.com - November 13 at 3:48 PM
ETFs with exposure to The Medicines Co. : November 13, 2017ETFs with exposure to The Medicines Co. : November 13, 2017
finance.yahoo.com - November 13 at 3:48 PM
The Medicines Company (MDCO) Receives Average Recommendation of "Hold" from AnalystsThe Medicines Company (MDCO) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 13 at 3:06 PM
CHMP recommends EU marketing authorization for ADYNOVI® [Antihemophilic Factor (Recombinant), PEGylated] for adults and adolescents with Hemophilia ACHMP recommends EU marketing authorization for ADYNOVI® [Antihemophilic Factor (Recombinant), PEGylated] for adults and adolescents with Hemophilia A
feeds.benzinga.com - November 13 at 3:22 AM
The Medicines Co. :MDCO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 10, 2017The Medicines Co. :MDCO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 10, 2017
finance.yahoo.com - November 12 at 6:01 AM
Late-stage development of Alnylams inclisiran to commence by year-endLate-stage development of Alnylam's inclisiran to commence by year-end
seekingalpha.com - November 8 at 5:39 PM
The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran - Business Wire (press release)The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran - Business Wire (press release)
www.businesswire.com - November 7 at 6:43 AM
Implied Volatility Surging for The Medicines Company (MDCO) Stock OptionsImplied Volatility Surging for The Medicines Company (MDCO) Stock Options
finance.yahoo.com - October 31 at 3:39 AM
TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedureTiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure
feeds.benzinga.com - October 31 at 2:47 AM
The Medicines Company (MDCO) to Post FY2017 Earnings of ($8.93) Per Share, Oppenheimer Holdings ForecastsThe Medicines Company (MDCO) to Post FY2017 Earnings of ($8.93) Per Share, Oppenheimer Holdings Forecasts
www.americanbankingnews.com - October 30 at 3:24 AM
Medicines Company (MDCO) Reports Q3 Loss, Revenues Miss - NasdaqMedicines Company (MDCO) Reports Q3 Loss, Revenues Miss - Nasdaq
www.nasdaq.com - October 28 at 8:04 AM
The Medicines Company Expected to Post FY2017 Earnings of ($9.10) Per Share (MDCO)The Medicines Company Expected to Post FY2017 Earnings of ($9.10) Per Share (MDCO)
www.americanbankingnews.com - October 27 at 7:54 AM
The Medicines (MDCO) CEO Clive Meanwell on Q3 2017 Results - Earnings Call TranscriptThe Medicines' (MDCO) CEO Clive Meanwell on Q3 2017 Results - Earnings Call Transcript
www.msn.com - October 27 at 6:37 AM
Medicines Co. reports 3Q lossMedicines Co. reports 3Q loss
finance.yahoo.com - October 27 at 6:37 AM
Medicines Co. shares surge 8% on planned restructuring, layoffsMedicines Co. shares surge 8% on planned restructuring, layoffs
finance.yahoo.com - October 27 at 6:37 AM
Edited Transcript of MDCO earnings conference call or presentation 25-Oct-17 12:30pm GMTEdited Transcript of MDCO earnings conference call or presentation 25-Oct-17 12:30pm GMT
finance.yahoo.com - October 27 at 6:37 AM
The Medicines Company Is Making A Dangerous Bet On A Drug To Lower LDL CholesterolThe Medicines Company Is Making A Dangerous Bet On A Drug To Lower LDL Cholesterol
finance.yahoo.com - October 27 at 6:37 AM
The Medicines Company (MDCO) Given a $50.00 Price Target at Oppenheimer Holdings, Inc.The Medicines Company (MDCO) Given a $50.00 Price Target at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - October 26 at 4:08 PM
Jefferies Group LLC Reiterates Buy Rating for The Medicines Company (MDCO)Jefferies Group LLC Reiterates Buy Rating for The Medicines Company (MDCO)
www.americanbankingnews.com - October 26 at 2:46 PM
The Medicines Company (MDCO) Releases  Earnings Results, Beats Estimates By $0.95 EPSThe Medicines Company (MDCO) Releases Earnings Results, Beats Estimates By $0.95 EPS
www.americanbankingnews.com - October 25 at 10:31 AM
Medicines Co. +8% on restructuring, planned sale of infectious drug businessMedicines Co. +8% on restructuring, planned sale of infectious drug business
seekingalpha.com - October 25 at 8:32 AM
The Medicines Company Reports Third-Quarter 2017 Business and Financial Results - Business Wire (press release)The Medicines Company Reports Third-Quarter 2017 Business and Financial Results - Business Wire (press release)
www.businesswire.com - October 25 at 7:09 AM
The Medicines Company Reports Third-Quarter 2017 Business and Financial ResultsThe Medicines Company Reports Third-Quarter 2017 Business and Financial Results
finance.yahoo.com - October 25 at 7:09 AM
The Medicines Company (MDCO) Now Covered by Analysts at GuggenheimThe Medicines Company (MDCO) Now Covered by Analysts at Guggenheim
www.americanbankingnews.com - October 23 at 6:20 PM
The Medicines Company to Announce Third-Quarter 2017 Financial Results on October 25The Medicines Company to Announce Third-Quarter 2017 Financial Results on October 25
finance.yahoo.com - October 21 at 6:28 AM

SEC Filings

The Medicines (NASDAQ:MDCO) SEC Filings

DateFilerForm TypeView
12/11/2017
5:23 PM
ESHELMAN FREDRIC N (Reporting)
The Medicines (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
12/06/2017
3:24 PM
The Medicines (Filer)
Form CT ORDER
View Filing
12/04/2017
4:18 PM
The Medicines (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
View Filing
12/01/2017
4:47 PM
The Medicines (Issuer)
Panayiotopoulos Paris (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
11/30/2017
6:30 AM
DENNER ALEXANDER J (Reporting)
The Medicines (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing

Social Media

Financials

The Medicines (NASDAQ:MDCO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

The Medicines (NASDAQ MDCO) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.